title: Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment.
authors.affiliation: Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Carlo
authors.initials: C
authors.lastname: Salvarani
authors.forename: Robert D
authors.initials: RD
authors.lastname: Brown
authors.forename: Kenneth T
authors.initials: KT
authors.lastname: Calamia
authors.forename: John
authors.initials: J
authors.lastname: Huston
authors.forename: James F
authors.initials: JF
authors.lastname: Meschia
authors.forename: Caterina
authors.initials: C
authors.lastname: Giannini
authors.forename: Dylan V
authors.initials: DV
authors.lastname: Miller
authors.forename: Gene G
authors.initials: GG
authors.lastname: Hunder
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001706:Biopsy; D004351:Drug Resistance; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D020293:Vasculitis, Central Nervous System / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept